Analyst Predictions On BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) Future Growth – Stocks Register
Home  »  Companies   »  Analyst Predictions On BioCryst Pharmaceuticals In...

Analyst Predictions On BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) Future Growth

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) price is hovering lower on Wednesday, September 15, dropping -2.65% below its previous close.

>> 7 Top Picks for the Post-Pandemic Economy <<

A look at today’s price movement shows that the recent level at last check reads $15.48, with intraday deals fluctuating between $15.43 and $16.12. The company’s 5Y monthly beta was ticking 2.59. Taking into account the 52-week price action we note that the stock hit a 52-week high of $18.48 and 52-week low of $3.30. The stock subtracted -4.15% on its value in the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


BioCryst Pharmaceuticals Inc., which has a market valuation of $2.78 billion, is expected to release its quarterly earnings report Nov 03, 2021 – Nov 08, 2021. Analysts tracking BCRX have forecast the quarterly EPS to shrink by -0.3 per share this quarter, while the same analysts predict the annual EPS to hit -$1.16 for the year 2021 and up to -$0.74 for 2022. In this case, analysts estimate an annual EPS growth of -6.40% for the year and 36.20% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $40.22 million, with the likely lows of $35 million and highs of $49 million. The average estimate suggests sales growth for the quarter will likely rise by 1,017.20% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $156.06 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 776.20% above that which the company brought in 2021.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give BCRX a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 12 analysts have assigned BCRX a recommendation rating as follows: 3 rate it as a Hold; 8 advise Buy while 1 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the BioCryst Pharmaceuticals Inc. (BCRX) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that BCRX’s price is at present -1.26% off the SMA20 and -5.31% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 44.38, with weekly volatility standing at 4.48%. The indicator jumps to 4.22% when calculated based on the past 30 days. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s beta value is holding at 2.59, while the average true range (ATR) indicator is currently reading 0.79. Considering analysts have assigned the stock a price target range of $16.00-$30.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $21.27. Based on this estimate, we see that today’s price at last check is roughly -6.17% off the estimated low and -99.07% off the forecast high. Investors will no doubt be excited to see the share price fall to $21.00, which is the median consensus price, and at that level BCRX would be -39.35% from recent price.

Turning out attention to how the BioCryst Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: BCRX’s stock is -2.65% on the day and 284.12% in the past 12 months, while CEL-SCI Corporation (CVM) traded 5.98% in the latest session and is positioned -18.86% down on its price 12 months ago. Another comparison is with Emergent BioSolutions Inc. (EBS) whose stock price is up 1.24% in the current trading session, and has flourished -45.05% over the past year. Also, Sarepta Therapeutics Inc. (SRPT) is currently showing up trend of 1.00% while its price kept floating at -42.04% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.27% in today’s early trading, with the Dow Jones Industrial also seeing a positive session on the day with 0.27%.

An analysis of the BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock in terms of its daily trading volume indicates that the 3-month average is 2.92 million. However, this figure increases on the past 10-day timeline to an average of 2.63 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Current records show that the company has 178.13M in outstanding shares. The insiders’ percentage holdings are 0.30% of outstanding shares while the percentage share held by institutions stands at 60.00%. The stats also highlight that short interest as of Jul 29, 2021, stood at 18.35 million shares, which puts the short ratio at the time at 7.62. From this we can glean that short interest is 10.26% of company’s current outstanding shares. Notably, we see that shares short in July fall slightly given the previous month’s figure stood at 19.15 million. But the 107.79% upside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam